UPCOMING SESSIONS in ET
Fri, Nov 20, 2026
6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness Hamide Eygoren Register
UPCOMING SESSIONS in ET
Fri, Nov 20, 2026 · 6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness
Hamide Eygoren
Register
View all sessions

Treatment and prognosis of immunoglobulin light chain (AL) amyloidosis

Key Information
summary/abstract

INTRODUCTION

Immunoglobulin light chain (AL) amyloidosis (previously referred to as primary amyloidosis) is a monoclonal plasma cell proliferative disorder characterized by tissue deposits of fibrils composed of monoclonal light chain fragments, leading to organ dysfunction.

The incidence of AL amyloidosis is approximately one-fifth that of multiple myeloma (MM). At the time of diagnosis, approximately 10 percent of patients with AL amyloidosis will meet diagnostic criteria for MM as defined by CRAB (hypercalcemia, renal insufficiency, anemia, or bone disease) criteria; nearly another 40 percent of patients with AL do not meet criteria for MM but have 10 percent or more bone marrow plasmacytosis at diagnosis. The clinical course and treatment of these patients are dependent on which of the two diseases is dominant in terms of end-organ damage and symptoms. Less than 1 percent of patients with isolated AL amyloidosis at diagnosis develop MM at a future time point.